BioSpace News Archive

Biohaven’s verdiperstat was selected as one of the first three drug candidates to be studied in the innovative HEALEY ALS Platform Trial at MGH

Cipher Pharmaceuticals Inc. (TSX: CPH) (“Cipher” or “the Company”) today announced it will release its Q4 2020 financial results after the close on Thursday, March 18, 2021.

The U.S., British, E.U. and Canadian governments all have pre-purchased enough COVID vaccine doses to inoculate their populations many times over while vaccine access in the rest of the world remains limited.

Burning Rock Biotech Limited, a company focused on the application of next generation sequencing technology in the field of precision oncology, reported financial results for the three months and year ended December 31, 2020.

Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease, today announced that four abstracts highlighting the Company’s lead program, tebentafusp, were accepted at the American Association for Cancer Research (AACR) 2021 Annual Meeting

Additive Orthopaedics, LLC., the leader in 3D printed orthopaedic foot and ankle devices, announces the launch of a new educational website focused on the Patient Specific Talus Spacer.

Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the latest preclinical research results of the company’s five novel drug candidates have been selected for presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021,

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, announced that CEO Snehal Patel will be interviewed live on Benzinga’s Power Hour on Thursday, March 11, 2021 at 12:30 pm EST.

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data on three XmAb® bispecific antibody programs and the IL-12-Fc cytokine program at the American Association for Cancer Research (AACR) Annual Meeting,

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that an Independent Data Monitoring Committee (IDMC) recommended that the Phase 3 COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial - Intent to Care Early) trial evaluating VIR-7831 (GSK4182136) as monotherapy for the early treatment of COVID-19 in adults at high risk of hospitalization be stopped for enrollment due to evidence of profound efficacy